Hitachi, Ltd. has entered a strategic framework collaboration agreement with the world-renowned medical research institution, Brigham and Women's Hospital (BWH). The partnership aims to establish a joint site for "co-creation" to accelerate efforts in gene and cell therapy (GCT) to conquer intractable diseases and realize practical applications. 

By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases. The goal is to develop new disease models through this joint research and contribute to increasing the scope of GCT application to various diseases.

Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT. In addition, Hitachi is developing a highly efficient technique to create genetically modifiesd cells for GCT, and from this collaboration framework will look to apply this technology in the development of new therapy with researchers and pharmaceutical companies in the US and worldwide.

BWH is a founding member of Mass General Brigham healthcare system and a faculty affiliate of Harvard Medical School. Over 400 researchers are working on ground-breaking gene and cell therapy research and treatment at Mass General Brigham, making it a world leader in GCT research and clinical trials.